AdBio partners

[Portfolio news] Congratulations to Tenpoint Therapeutics, Ltd. and Visus Therapeutics on their merger! This announcement marks a new era in groundbreaking ophthalmic medicines aimed at rejuvenating the aging eye. The product initially financed by AdBio partners through the french company GCT, founded by Deniz Dalkara and Olivier Goureau from Inserm, has been selected as one of the three innovative programs brought together by the merger. The new pipeline includes BRIMOCHOL™ PF, a presbyopia-correcting eye drop, TPT-161, a small molecule designed to reverse cataract formation, and the GCT product TPT-005, a cell therapy targeting RPE cell replacement for geographic atrophy. #Innovation #Ophthalmology #Healthcare Henric Bjarke Ben Bergo

[Portfolio news] At AdBio partners, we’re always inspired by the dedication of our portfolio companies to bring meaningful change to patients' lives. Today we’re proud to share the journey from our portfolio company ARTHEx Biotech. In a recent recording, Dr. beatriz llamusi, CSO & Co-Founder, and Dr. Judith Walker, CMO, discussed the latest developments in their clinical trial for a potential treatment for myotonic dystrophy type 1 (DM1). Their insights highlight the groundbreaking work being done to address this devastating genetic disorder and bring hope to patients and families who have long been waiting for innovative solutions. Listen to the full recording to learn about the ARTHEx Biotech journey, their science, and their vision for a better future for patients with DM1. #AdBioPartners #PatientsFirst #MyotonicDystrophy #ClinicalTrials #HopeForPatients #BiotechInnovation Myotonic Dystrophy Foundation Frederic LEGROS

[Event] Last week took place in Valencia the CIBER Congress, celebrating 10 years of scientific collaboration by Consortium Centro de Investigación Biomédica en Red CIBER, a leading Spanish platform for biomedical and translational research, promoted by the Instituto de Salud Carlos III (ISCIII). It connects over 500 research groups nationwide, integrating hospitals, universities and research centers. It was a privilege for our Partner Emma Gasol Escuer to join the fellow panelists—Eva Ortega-Paino, Ion Arocena, Amelia Martín Uranga, Raúl Martín-Ruiz, and Elena Gobartt — to discuss the role of public-private collaboration in advancing biomedical research and innovation. A few key takeaways from the session: 🤝 Collaboration is key: Platforms like CIBER excel at fostering connections across disciplines “without walls”, vital to accelerating the translation of discoveries into impactful solutions. 🌐 The value of industry and VC partners: they play a crucial role by providing not only funding at these early stages but expertise and market-driven insights that bridge the gap between innovation and commercialization. 🔎 Exploring de-risking early-stage models: involves implementing structured frameworks, public-private co-investment initiatives to validate scientific potential and generate a ready data package to attract further investment 🔬 Tech transfer offices are a key entry point, bridging academia and VCs/industry, facilitating the commercialization of research and incentivising the entrepreneurial spirit. Spain is a great ground for life sciences innovation and we are committed about the road ahead! 🚀 Ministerio de Ciencia, Tecnología e Innovación AseBio - Asociación Española de Bioempresas FARMAINDUSTRIA Ysios Capital Boehringer Ingelheim   #CIBERValencia #ISCIII #TechTransfer #AndzonBio

[Portfolio news] We are thrilled to share that Colin Bond has joined Agomab an Independent Director and Chairman of the Audit Committee. Colin’s extensive financial leadership, with over 30 years of expertise, including his tenure as CFO at Sandoz, positions him perfectly to support Agomab 's continued growth. Colin’s experience spans strategic roles at global pharmaceutical leaders, and his track record in guiding companies through pivotal growth stages will be invaluable as Agomab advances its portfolio targeting fibrotic diseases. At AdBio partners, we take immense pride in seeing our portfolio companies attract top-tier talent to fuel their ambitions. Congratulations to Colin Bond – we’re excited to see what’s next!  Tim Knotnerus David Epstein Alain Huriez #Leadership #AgomabTherapeutics #Biotech #LifeSciences #VentureCapital

[Event] Last Friday, our Managing Partner Alain Huriez, represented AdBio partners at the Falling Walls Science Summit24 in Berlin, sharing insights on the role of early-stage #investment in driving equitable access to innovative medical therapies. Alain highlighted AdBio partners' commitment as both a company builder and early-stage fund to bridging the gap between cutting-edge scientific discovery and real-world impact. A big thank you to the Falling Walls Foundation and Berlin Institute of Health for the opportunity to contribute to this essential discussion, as well as to the great panel we have been part of Beate Kampmann, Jennifer Adair, Jimi Olaghere and Christof von Kalle. We look forward to continued collaborations that make a difference in global healthcare. #AdBioPartners #CompanyBuilder #EarlyStageVC #FallingWalls #HealthcareInnovation #GlobalAccess

[Portfolio news] At AdBio partners, we are deeply committed to creating and shaping innovative companies from their earliest stages, transforming scientific breakthroughs into impactful therapies. We’re proud to announce today the launch of AndzonBio1 with a first €3M financing with Inserm Transfert. As the first in a series of thematic studios within AndzonBio, AndzonBio1 will focus on Cardiovascular, Renal, and Metabolic (CVRM) diseases—a field with important unmet medical needs. Through AndzonBio, we are pursing our #HandsOn mission, accelerating science, guiding promising ideas from the lab towards the patients. Stay tuned for updates here : https://andzonbio1.com/ Karine Charton Vincent Bischoff Loïc Lhuillier Alain Huriez

[Portfolio news] We are excited to announce a $89 million Series D financing round for our portfolio company Agomab, lead by new investors Sanofi and The Invus Group. Agomab is developping a pipeline of therapies for Fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. These innovations aim to tackle the significant challenges patients face everyday, including pain and the need for surgery. At AdBio partners, we remain committed to supporting solutions that have a meaningful impact on patients' lives. Congratulations to the team on this important milestone! #AdBio #UnmetNeeds #PatientImpact #Innovation Tim Knotnerus Alain Huriez

[Portfolio news] We’re proud to share that ARTHEx Biotech, a company we have supported since 2020, has dosed its first patient in the Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1 (DM1)! This is a great success for ARTHEx Biotech, and a powerful validation of our model at AdBio partners — shaping early-stage, high-potential innovations and guiding them all the way to the clinic. 💡 From the first check to the first patient, we’ve believed in the potential of the project, the industry’s first anti-microRNA therapeutic for DM1. It’s moments like these — bringing transformative therapies to patients — that fuel our vision and drive us every day. This is why we do what we do. Huge congratulations to the entire Arthex team! Frederic LEGROS Judith Walker beatriz llamusi Alain Huriez Adrien C.

[Job offer] AdBio partners is strengthening its team in Spain and #hiring an Analyst based in the Barcelona Office. Join a dynamic team dedicated to transform academic research into therapies for patients ! Check out the offer below 👇 Please submit your resume and cover letter to [email protected]

[Portfolio news] We're proud to highlight the innovative work of one of our portfolio companies! Under the leadership of Dr. Frederic LEGROS, ARTHEx Biotech focus on microRNA modulation for the treatment of myotonic dystrophy type 1 is gaining attention at the forefront of #GeneticMedicines. Don't miss the chance to meet Dr. Legros during Chardan's 8th Annual Genetic Medicines Conference in New York next week. Their cutting-edge approach is one to watch in the evolving field of #myotonicdystrophy #CGMC2024 #biotech #ChardanGMConf #AdBioPartners #InnovationInHealth beatriz llamusi